Skip to textbook content
Doctor’s PassportTextbook
QuestionsFlashcardsBriefsDashboardAccount
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Cardiac disease and pregnancy risk

Obstetrics and gynaecology · UK scope · Sources checked 7 Sept 2026 · Clinical review pending

RapidFull
!
Cardiac symptoms require maternal stabilisation first

Acute chest pain, syncope, hypoxia, pulmonary oedema or sustained arrhythmia may represent life-threatening disease during pregnancy or after birth.

Action: Call senior medical, cardiology, obstetric and anaesthetic support, assess ABCDE with ECG and oxygenation, and perform necessary imaging and treatment promptly; pregnancy should not delay cardioversion, defibrillation or life-saving investigation.

Synopsis

Recognise cardiac symptoms that exceed normal pregnancy physiology, assess lesion-specific maternal risk and coordinate a pregnancy heart team plan through the vulnerable postpartum period.

  • Assess the actual lesion, ventricular function, symptoms, pulmonary pressure, aortic dimensions and prior events; a diagnosis name alone is insufficient.
  • Use the ESC 2025 mWHO 2.0 framework and involve a Pregnancy Heart Team for mWHO II–III or greater risk.
  • Severe ventricular dysfunction, pulmonary arterial hypertension, major aortopathy and severe valve obstruction can confer very high risk and need expert counselling.
  • Transthoracic echocardiography is the initial structural imaging test for suspected heart disease and is safe in pregnancy.
  • Vaginal birth is suitable for many cardiac conditions; delivery mode, analgesia, monitoring and uterotonics should follow the individual haemodynamic plan.
  • Mechanical valves need a specialist anticoagulation plan balancing maternal thrombosis and fetal risk; standard VTE prophylaxis is inadequate.
  • Acute unstable tachyarrhythmia may require synchronised cardioversion, while regular stable narrow-complex SVT can be treated with vagal manoeuvres and monitored adenosine.
  • Postpartum fluid shifts can trigger decompensation, so significant disease requires planned observation and follow-up after birth.

Key red flags

New orthopnoea, paroxysmal nocturnal dyspnoea, resting breathlessness, hypoxia or haemoptysis needs urgent assessment for cardiac failure or pulmonary embolism.

Syncope with exertion, chest pain, a sustained rapid rhythm or family history of sudden death requires urgent cardiac evaluation.

Sudden tearing chest or back pain with aortopathy, pulse inequality or neurological symptoms raises concern for aortic dissection.

Investigation priorities

01
12-lead ECG and rhythm monitoringFirst step

Identify arrhythmia, conduction abnormalities or evidence of myocardial injury.

Management branches

Risk assessmentBuild a lesion-specific pregnancy plan

Known heart disease is identified before conception or during antenatal booking.

  1. Retrieve prior imaging, operations, functional status, arrhythmia history and medicine or anticoagulation details.
  2. Assign contemporary cardiac risk with the specialist team and identify the required tertiary services and emergency access arrangements.
  3. Agree surveillance, fetal assessment, birth planning and postpartum care with the patient, revisiting decisions as physiology changes.

Key medicines

Furosemide for acute pulmonary oedemaA product-supported initial dose is 20–40 mg intravenously by slow injection, at no more than 4 mg/minute; reassess response and consider a further dose after 30–60 minutes under senior supervision.Avoid indiscriminate diuresis in preload-dependent lesions or hypovolaemia; monitor blood pressure, urine output, electrolytes and renal function and assess fetal wellbeing.
Adenosine for regular narrow-complex SVTUnder the RCUK 2025 adult algorithm give 6 mg by rapid intravenous bolus with an immediate flush, then 12 mg if unsuccessful and 18 mg if still unsuccessful, with continuous ECG and resuscitation facilities.Exclude pre-excitation and relevant contraindications, including severe asthma; urgent cardioversion takes priority in instability. This guideline sequence differs from some product SmPC schedules and requires protocol-based prescribing.
Open full textbook →Answer 2 questions
Sources and review status6 sources · checked 7 Sept 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

  • ESC 2025: Cardiovascular disease and pregnancy guideline
  • NICE NG121: Intrapartum care with heart disease
  • RCUK 2025: Special circumstances including pregnancy
  • RCUK 2025 adult tachyarrhythmia algorithm: January 2026 revision
  • Furosemide injection: acute pulmonary oedema SmPC
  • Adenosine injection: product cautions and pregnancy information

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom